Department of Pharmacology, Hangzhou City, 310058, China.
The Key Respiratory Drug Research Laboratory of China Food and Drug Administration, School of Medicine, Zhejiang University, Hangzhou City, 310058, China.
Clin Pharmacol Ther. 2018 Sep;104(3):484-494. doi: 10.1002/cpt.1034. Epub 2018 Feb 27.
Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the "omics" approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
尽管经过了 50 年的广泛研究，但目前仍没有明确的药物可用于治疗急性呼吸窘迫综合征（ARDS），支持性治疗仍然是治疗的主要手段。为了改善 ARDS 的药物开发，研究人员需要深入分析“组学”方法，重新评估合适的治疗靶点，解决动物模型不足的问题，制定减少异质性的策略，并重新考虑新的治疗和分析方法，以更好地设计临床试验。
